Metropolis Healthcare Limited has informed the Exchange about Sale of EQAS Division

Core Business DivestedStrategic Transactions View source PDF Explain this filing

METROPOLIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.8%Reaction day

₹478.70

prior close

₹481.10

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.0%+3.8% vs market

Healthcare Service Provider peers, median of 24sector+0.2%+2.6% vs sector

On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 2.6 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.0

15m

+0.2

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.8-1.0+3.8+0.2+2.6

Next day

+3.7-1.8+5.5+1.3+2.3

+4.1+0.8+3.3+1.5+2.5

+3.9+1.8+2.2+1.5+2.4

+4.2+1.2+3.0+1.5+2.8

+3.3+0.7+2.6+0.2+3.1

+1.1-1.5+2.6+1.2-0.1

15d

-1.3-2.5+1.2-3.3+2.0

-6.3-7.2+0.9-5.3-1.0

-10.1-8.9-1.2-7.8-2.3

+5.6+5.5+0.1-2.5+8.1

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Metropolis Healthcare has informed the stock exchange about the sale of its EQAS (External Quality Assessment Scheme) Division. EQAS is the part of the business that provides quality control and proficiency testing services to other pathology labs. The company has not yet disclosed the buyer, deal value, or timeline in this filing. Such a sale would streamline Metropolis's focus on its main diagnostic and pathology testing services. Shareholders will need to wait for further details on the financial impact and use of proceeds.

Likely market impact

Divesting EQAS may help Metropolis sharpen focus on its core diagnostic business, but investors should watch for the deal value and whether the sale proceeds will be used for growth, debt reduction, or shareholder returns. Near-term stock reaction will depend on the price fetched for the division.